ReviewExpert review of clinical immunology2010
Duloxetine for the treatment of fibromyalgia.
Review in Expert review of clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03487211 (Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis.Journal of orthopaedic surgery and research · 2023Pooled it
- Recent Developments in Pharmacotherapy of Depression: Bench to Bedside.Journal of personalized medicine · 2023Review
- Review
- Pain associated with breast cancer: etiologies and therapies.Frontiers in pain research (Lausanne, Switzerland) · 2023Review
- Pharmacological Interaction of Quercetin Derivatives ofMetabolites · 2022Article
- The P2X4 Receptor: Cellular and Molecular Characteristics of a Promising Neuroinflammatory Target.International journal of molecular sciences · 2022Review
- Managing Bipolar Disease Complicated with Psychosis in Conjunction with Polypharmacy, Parkinson's Disease, and Multiple Comorbidities.Case reports in psychiatry · 2022Article
- Fibromyalgia: Recent Advances in Diagnosis, Classification, Pharmacotherapy and Alternative Remedies.International journal of molecular sciences · 2020Review
- Targeting Pathological Tau by Small Molecule Inhibition of the Poly(A):MSUT2 RNA-Protein Interaction.ACS chemical neuroscience · 2020Article
- Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders.Frontiers in endocrinology · 2020Review
- Polypharmacy, Opioid Use, and Fibromyalgia: A Secondary Analysis of Clinical Trial Data.Biological research for nursing · 2017Article
- Polyelectrolyte Hydrogel Platforms for the Delivery of Antidepressant Drugs.Gels (Basel, Switzerland) · 2016Article
- The search for novel analgesics: targets and mechanisms.F1000prime reports · 2015Review
- Predictors of duloxetine adherence and persistence in patients with fibromyalgia.Journal of pain research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This article presents a brief review of the physiologic abnormalities seen in fibromyalgia, current theories of widespread pain, and treatment options, including emerging therapeutics, with a focus on the use of duloxetine to manage fibromyalgia symptoms. Major clinical trials that examine the efficacy and effectiveness of duloxetine to date are reviewed, and safety issues are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.